• 
• Print
• Email
• Order a PDF

Sunovion Pharmaceuticals is divesting its allergy and asthma products to focus more heavily on its products that treat chronic obstructive pulmonary disease.

The company said Thursday that it will divest its U.S. market rights to asthma and allergy products to Covis Pharma, a Swiss company. The transaction is expected to close during the first half of fiscal year 2017, and Covis will ship all products immediately following the closing, according to Sunovion.

The divestiture will allow Sunovion to advance its COPD portfolio, according to the company.

• 
• Print
• Email
• Order a PDF